Lovastatin

DEA Class; Rx

Common Brand Names; Mevacor, Altoprev

  • Lipid-Lowering Agents, Statins; 
  • HMG-CoA Reductase Inhibitors

Oral antilipemic agent; HMG-CoA reductase inhibitor; used for hypercholesterolemia.

 

Indicated

For the treatment of hypercholesterolemia, including hyperlipidemia, hyperlipoproteinemia, or hypertriglyceridemia, as an adjunct to dietary control.

For myocardial infarction prophylaxis (primary prevention).
For myocardial infarction prophylaxis (primary prevention).
For slowing the progression of atherosclerosis in patients with carotid artery disease (i.e., stroke prophylaxis).

Hypersensitivity to lovastatin or other components

Active liver disease, or unexplained elevated transaminases

Concomitant administration with strong CYP3A4 inhibitors (eg, itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, cobicistat, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, and nefazodone)

CPK elevation (11%)

Flatulence (4-5%)

Abdominal pain (2-3%)

Constipation (2-3%)

Diarrhea (2-3%)

Myalgia (2-3%)

Nausea (2-3%)

Dyspepsia (1-2%)

Weakness (1-2%)

Blurred vision (0.8-1%)

Rash (0.8-1%)

Muscle cramps (0.6-1%)

Dizziness (0.5-1%)

<1%

Dermatomyositis

Increased LFTs

Hepatotoxicity

Myopathy

Rhabdomyolysis

Interstitial lung disease

Nonserious and reversible cognitive side effects may occur

Avoid coadministration with cyclosporine or gemfibrozil; caution with other fibrates or lipid-lowering doses of niacin (≥1 g/day) because of increased risk for myopathy

Use caution in heavy alcohol use, history of liver disease, or renal failure

Obtain baseline liver enzyme tests before initiating and then periodically thereafter

Increases in HbA1c and fasting serum glucose levels reported

HMG-CoA reductase inhibitor shown to reduce plasma testosterone response to HCG; effects of HMG-CoA reductase inhibitors on male fertility not studied in adequate numbers of male patients

Effects of therapy, if any, on pituitary-gonadal axis in premenopausal women are unknown; patients who develop clinical evidence of endocrine dysfunction should be evaluated appropriately

Use caution if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., spironolactone, cimetidine) that may decrease levels or activity of endogenous steroid hormones

Risk of myopathy increased by coadministration of CYP3A4 inhibitors or other drugs that cause myopathy

Owing to HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, fetal harm may occur when administered to pregnant females

There is no available information on effects of drug on breastfed infant or on milk production

Unknown whether is present in human milk; it has been shown that drugs in this class pass into human milk and atorvastatin is present in rat milk

Not recommended during treatment

Adults

80 mg/day PO immediate-release tablets (e.g., Mevacor); 60 mg/day PO extended-release tablets (Altoprev). Max 20 mg/day PO immediate-release or extended-release lovastatin if taking fibrates, niacin, danazol, or cyclosporine; max 40 mg/day PO immediate-release lovastatin if taking amiodarone or verapamil; max 20 mg/day PO extended-release lovastatin if taking amiodarone or verapamil.

Geriatric

80 mg/day PO immediate-release tablets (e.g., Mevacor); 60 mg/day PO extended-release tablets (Altoprev). Max 20 mg/day PO immediate-release or extended-release lovastatin if taking fibrates, niacin, danazol, or cyclosporine; max 40 mg/day PO immediate-release lovastatin if taking amiodarone or verapamil; max 20 mg/day PO extended-release lovastatin if taking amiodarone or verapamil.

Adolescents

40 mg/day PO immediate-release tablets (e.g., Mevacor). Safety and efficacy have not been established for extended-release tablets (e.g., Altoprev).

Children

10 years and older: 40 mg/day PO immediate-release tablets (e.g., Mevacor). Safety and efficacy have not been established for extended-release tablets (e.g., Altoprev).
Less than 10 years: Safety and efficacy have not been established.

Lovastatin

tablets, extended-release

  • 20mg
  • 40mg
  • 60mg

tablets

  • 10mg
  • 20mg
  • 40mg

About the Author

You may also like these

0